PMID- 27500463
OWN - NLM
STAT- MEDLINE
DCOM- 20170508
LR  - 20171116
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 135
IP  - 4
DP  - 2017 Apr
TI  - Upper motor neuron evaluation in multiple sclerosis patients treated with
      Sativex((R)).
PG  - 442-448
LID - 10.1111/ane.12660 [doi]
AB  - BACKGROUND: Spasticity in multiple sclerosis (MS) results from an imbalance of
      inputs from descending pathways to the spinal motor circuits, as well as from a
      damage of the corticospinal tract (CST). OBJECTIVES: To assess CST impairment in 
      MS patients with and without spasticity and to evaluate its evolution under
      Sativex((R)) treatment. METHODS: Ten MS patients with spasticity ("cases")
      underwent clinical (EDSS, 9-hole Peg, Ashworth scale, Timed 25-Foot Walk, and NRS
      for spasticity), MRI (CST fractional anisotropy [FA]), and electrophysiological
      (central motor conduction time [CMCT] and H/M ratio) evaluations at baseline and 
      after 12 months. We selected 20 MS patients without spasticity as control group
      at baseline. RESULTS: At baseline, cases showed a lower CST FA (0.492+/-0.045 vs 
      0.543+/-0.047; P=.01) and a higher CMCT (P=.001) compared to the control group.
      No correlations were found between clinical, electrophysiological, and MRI
      features. After 12 months, cases showed a decrease in non-prevalent degree of
      impairment (PDI) side FA (0.502+/-0.023 vs 0.516+/-0.033; P=.01) without
      differences for electrophysiological features compared to baseline. Treatment
      with Sativex((R)) resulted in a reduction of NRS for spasticity (P=.01).
      CONCLUSIONS: We confirm the presence of CST impairment in MS patients with
      spasticity. We did not identify structural/electrophysiological correlates that
      could explain Sativex((R)) clinical effect.
CI  - (c) 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Carotenuto, A
AU  - Carotenuto A
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences,
      Federico II University of Naples, Naples, Italy.
FAU - Iodice, R
AU  - Iodice R
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences,
      Federico II University of Naples, Naples, Italy.
FAU - Petracca, M
AU  - Petracca M
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences,
      Federico II University of Naples, Naples, Italy.
AD  - Department of Neurology, Radiology, Neuroscience, Icahn School of Medicine, Mount
      Sinai, NY, USA.
FAU - Inglese, M
AU  - Inglese M
AD  - Department of Neurology, Radiology, Neuroscience, Icahn School of Medicine, Mount
      Sinai, NY, USA.
FAU - Cerillo, I
AU  - Cerillo I
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences,
      Federico II University of Naples, Naples, Italy.
FAU - Cocozza, S
AU  - Cocozza S
AD  - Department of Advanced Biomedical Sciences, Federico II University of Naples,
      Naples, Italy.
FAU - Saiote, C
AU  - Saiote C
AD  - Department of Neurology, Icahn School of Medicine, Mount Sinai, NY, USA.
FAU - Brunetti, A
AU  - Brunetti A
AD  - Department of Advanced Biomedical Sciences, Federico II University of Naples,
      Naples, Italy.
FAU - Tedeschi, E
AU  - Tedeschi E
AD  - Department of Advanced Biomedical Sciences, Federico II University of Naples,
      Naples, Italy.
FAU - Manganelli, F
AU  - Manganelli F
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences,
      Federico II University of Naples, Naples, Italy.
FAU - Orefice, G
AU  - Orefice G
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences,
      Federico II University of Naples, Naples, Italy.
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20160808
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Drug Combinations)
RN  - 0 (Plant Extracts)
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 7J8897W37S (Dronabinol)
RN  - K4H93P747O (nabiximols)
SB  - IM
MH  - Adult
MH  - Cannabidiol
MH  - Dronabinol
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Motor Neurons/drug effects
MH  - Multiple Sclerosis/complications/*drug therapy
MH  - Muscle Spasticity/*drug therapy/etiology
MH  - Plant Extracts/adverse effects/pharmacology/*therapeutic use
MH  - Pyramidal Tracts/drug effects
OTO - NOTNLM
OT  - *Sativex
OT  - *corticospinal tract
OT  - *electrophysiological assessment
OT  - *multiple sclerosis
OT  - *spasticity
EDAT- 2016/08/09 06:00
MHDA- 2017/05/10 06:00
CRDT- 2016/08/09 06:00
PHST- 2016/07/14 00:00 [accepted]
PHST- 2016/08/09 06:00 [pubmed]
PHST- 2017/05/10 06:00 [medline]
PHST- 2016/08/09 06:00 [entrez]
AID - 10.1111/ane.12660 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2017 Apr;135(4):442-448. doi: 10.1111/ane.12660. Epub 2016 Aug
      8.